John Strickler

Positions:

Associate Professor of Medicine

Medicine, Medical Oncology
School of Medicine

Member of the Duke Cancer Institute

Duke Cancer Institute
School of Medicine

Education:

M.D. 2005

University of Chicago

Residency, Medicine

University of Washington

Fellowship in Hematology-Oncology, Medicine

Duke University School of Medicine

Grants:

CGX1321-101

Administered By
Duke Cancer Institute
Role
Principal Investigator
Start Date
End Date

CO40939

Administered By
Duke Cancer Institute
Role
Principal Investigator
Start Date
End Date

Nektar

Administered By
Duke Cancer Institute
Role
Principal Investigator
Start Date
End Date

AbbVie M14-064

Administered By
Duke Cancer Institute
Role
Principal Investigator
Start Date
End Date

AbbVie M16-438

Administered By
Duke Cancer Institute
Role
Principal Investigator
Start Date
End Date

Publications:

Abstract 1675: Analytical validation of MSI High detection with GuardantOMNI

Authors
Zhao, J; Artyomenko, A; Artieri, C; Latham, J; Fairclough, SR; Barbacioru, C; Helman, E; Strickler, J; Chudova, D; Lanman, R; Talasaz, A
MLA Citation
Zhao, Jing, et al. “Abstract 1675: Analytical validation of MSI High detection with GuardantOMNI.” Bioinformatics, Convergence Science, and Systems Biology, American Association for Cancer Research, 2019. Crossref, doi:10.1158/1538-7445.am2019-1675.
URI
https://scholars.duke.edu/individual/pub1416462
Source
crossref
Published In
Bioinformatics, Convergence Science, and Systems Biology
Published Date
DOI
10.1158/1538-7445.am2019-1675

Abstract LB-235: COLOMATE: Colorectal cancer and liquid biopsy screening protocol for molecularly assigned therapy

Authors
Ciombor, KK; Ou, F-S; Dodge, A; Zemla, T; Wu, C; Ng, K; Pedersen, K; Kato, S; Kasi, PM; Ahn, D; Nagy, R; Lanman, R; Kopetz, S; Strickler, JH; Bekaii-Saab, T
MLA Citation
Ciombor, Kristen K., et al. “Abstract LB-235: COLOMATE: Colorectal cancer and liquid biopsy screening protocol for molecularly assigned therapy.” Clinical Research (Excluding Clinical Trials), American Association for Cancer Research, 2019. Crossref, doi:10.1158/1538-7445.am2019-lb-235.
URI
https://scholars.duke.edu/individual/pub1416463
Source
crossref
Published In
Clinical Research (Excluding Clinical Trials)
Published Date
DOI
10.1158/1538-7445.am2019-lb-235

Blood-based genomic profiling of cell-free DNA (cfDNA) to identify microsatellite instability (MSI-H), tumor mutational burden (TMB) and Wnt/B-Catenin pathway alterations in patients with gastrointestinal (GI) tract cancers.

Authors
Isaacs, J; Nixon, AB; Bolch, E; Quinn, K; Banks, K; Hanks, BA; Strickler, JH
MLA Citation
Isaacs, James, et al. “Blood-based genomic profiling of cell-free DNA (cfDNA) to identify microsatellite instability (MSI-H), tumor mutational burden (TMB) and Wnt/B-Catenin pathway alterations in patients with gastrointestinal (GI) tract cancers..” Journal of Clinical Oncology, vol. 37, no. 15_suppl, American Society of Clinical Oncology (ASCO), 2019, pp. 3552–3552. Crossref, doi:10.1200/jco.2019.37.15_suppl.3552.
URI
https://scholars.duke.edu/individual/pub1414970
Source
crossref
Published In
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Volume
37
Published Date
Start Page
3552
End Page
3552
DOI
10.1200/jco.2019.37.15_suppl.3552

Prediction model for detecting circulating tumor DNA (ctDNA) in metastatic colorectal cancer (mCRC).

Authors
Pereira, AAL; Parikh, AR; Van Seventer, EE; Jia, J; Loree, JM; Kanikarla Marie, P; Raghav, KPS; Morris, VK; Overman, MJ; Raymond, VM; Lanman, RB; Talasaz, A; Strickler, JH; Corcoran, RB; Kopetz, S
MLA Citation
Pereira, Allan Andresson Lima, et al. “Prediction model for detecting circulating tumor DNA (ctDNA) in metastatic colorectal cancer (mCRC)..” Journal of Clinical Oncology, vol. 37, no. 15_suppl, American Society of Clinical Oncology (ASCO), 2019, pp. 3590–3590. Crossref, doi:10.1200/jco.2019.37.15_suppl.3590.
URI
https://scholars.duke.edu/individual/pub1414971
Source
crossref
Published In
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Volume
37
Published Date
Start Page
3590
End Page
3590
DOI
10.1200/jco.2019.37.15_suppl.3590

Results of the phase 1b study of ABBV-399 (telisotuzumab vedotin; teliso-v) in combination with erlotinib in patients with c-Met+ non-small cell lung cancer by EGFR mutation status.

Authors
Camidge, DR; Barlesi, F; Goldman, JW; Morgensztern, D; Heist, RS; Vokes, EE; Spira, AI; Angevin, E; Su, W-C; Hong, DS; Strickler, JH; Motwani, M; Sun, Z; Parikh, A; Noon, E; Wu, J; Kelly, K
MLA Citation
Camidge, D. Ross, et al. “Results of the phase 1b study of ABBV-399 (telisotuzumab vedotin; teliso-v) in combination with erlotinib in patients with c-Met+ non-small cell lung cancer by EGFR mutation status..” Journal of Clinical Oncology, vol. 37, no. 15_suppl, American Society of Clinical Oncology (ASCO), 2019, pp. 3011–3011. Crossref, doi:10.1200/jco.2019.37.15_suppl.3011.
URI
https://scholars.duke.edu/individual/pub1414972
Source
crossref
Published In
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Volume
37
Published Date
Start Page
3011
End Page
3011
DOI
10.1200/jco.2019.37.15_suppl.3011